SATURDAY
MAY 12TH

6:30 PM TO CLOSE
KING STREET GRILLE
(SOON TO BE CASTAWAY’S GRILLE)
ON JAMES ISLAND

$10 IN ADVANCE (THROUGH ETIX)

BTAM!!
2012

MUSC BRAIN & SPINE TUMOR PROGRAM PRESENTS:

BENEFIT CONCERT
& SILENT AUCTION
FOR MUSC BRAIN TUMOR RESEARCH

To find out more about BTAM events visit: MUSC.edu/neurosciences/BTAM

For questions or comments contact: Emma C. Vought at vought@musc.edu

Medical University of South Carolina Neurosciences
MUSC.edu/neurosciences
To find out more about Brain Tumor Action Month events visit: MUSC.edu/neurosciences/BTAM
Cover Image by Emma C. Vought

This newsletter was made possible from the generous contributions of faculty and staff in MUSC’s Neurosciences Department. The success of this publication is dependant upon this support. Thank you for your interest, time and information. For inquiries, suggestions or submission please contact Emma C. Vought (vought@musc.edu).

Table of Contents

Chairs’ Message ............................................................... 3
News ....................................................................................... 4-8
Publications & Employee Update............................... 9
Clinical Trials ....................................................................... 10-12
Grants...................................................................................... 13-14
Contact ................................................................................. 15

Editors:
Dr. Patel, Dr. Kalivas, Rachel Beard, and Emma C. Vought

Illustrations and Design:
Emma C. Vought

Submission Staff:
Rachel Beard and Emma C. Vought
Chairs’ Message
April, 2012

Spring is upon us. While New Year Resolutions may have slipped away, Spring is a time for rebirth, when we re-imagine what is possible for ourselves and our workplace. A time to open the windows of our minds and find new ways to invigorate our thinking about what we want the department of Neurosciences to become. Many new faculty and employees have arrived over the last year with ideas and experiences from other institutions and walks of life, giving us greater diversity of thought. We have seen excellent candidates for the Neurology Chair pass through and will soon have a new leader who will hybridize their background with our existing culture, creating a department that is at once clinically more facile, educationally invigorated and instill new ingenuity into our research mission. This is the leadership we are seeking and we have seen examples of this in some of the candidates. This newsletter is replete with various achievements and possibilities for our future. I urge us all to take time this Spring to think about a vision for ourselves in the work place, and for department as an instrument to enact that vision. Talk with your colleagues and leaders about your ideas for personal and departmental improvement. And, of course, take a moment to enjoy our beautiful Spring weather.

Sunil and Peter
Brain Tumor Action Month
May 2012

The primary goal of Brain Tumor Action Month is to raise awareness and convince others to join in the fight for an increase in funding for brain tumor research and the development of and access to better treatments.

Events:
Display Table: April 30 - May 4 (9 a.m. - 4 p.m.)
MUSC Hollings Cancer Center (1st floor lobby)
Stop by for free educational information, t-shirts for sale and a chance to enter a drawing for prizes.

Brain Tumor Action Fair: April 30 (11 a.m. - 2 p.m.)
MUSC Horseshoe
Mayor Riley and Mayor Swails will be in attendance!
Free information on support services, food vendors, gift items for sale and fundraising opportunities.

* Brain Tumor Vigil Service: May 3, (4 p.m. - 5 p.m.)
MUSC Hollings Cancer Center Healing Garden
Join us for this vigil in support of those who need healing and in remembrance of those who are no longer with us.

* Lecture “Why Seizures Occur in Brain Tumor Patients” May 2 (noon - 1 p.m.)
MUSC Ashley River Tower, Conference Room 1119
A lecture presented by MUSC’s Epilepsy Specialists: Gabriel Martz, M.D. and Leonardo Bonilha, M.D., Ph.D.

* Lecture “Nutrition & Healthy Living for Brain Tumor Patients” : May 4, 2012 (noon)
MUSC Baruch Auditorium, Conference Room QG103
A lecture presented by Michael Stafford, RD, CSO, LD, Outpatient Oncology Dietitian.

* Lecture “Current Trends in the management of Glioblastoma Multiforme”: May 8 (5:30 p.m.)
Anson Restaurant, Charleston, SC
Nicholas G. Avgeropoulos, M.D. will be presenting. This lecture is geared towards health care providers. To register please contact Amy Delaney; 803-378-7412 or amy.delaney@merck.com

Benefit Concert and Silent Auction
May 12 (6:30 p.m. until close)
King Street Grille, James Island, SC (soon to be Castaways Grille)
An evening of music and fun benefiting MUSC brain tumor research. This event features musicians: Mac Leaphart & My Ragged Company, Rawberry Jam, Taco Donkey and The Dubplates, drawings, silent auction and more. Tickets are $10 in advance through etix and $15 at the door.

* Fast Rounds: Answers to Questions We Forget to Ask When Diagnosed with a Brain Tumor: May 17 (5:30 p.m. - 7:30), Charleston Marriott
A series of short lectures on a variety of support services for patients. Drinks and appetizers will be served.

Brain Tumor Awareness Night at the Charleston RiverDogs Baseball Game: May 18 (7 p.m.)
Joe P. Riley Jr. Park, Charleston, SC
To purchase tickets visit: riverdogs.com

* Registration Required
Events are open to all and free unless otherwise noted.
For more information or to register for an event visit: MUSC.edu/neurosciences/BTAM
or contact Rachel Beard at beardr@musc.edu or 843-792-6592.

Upcoming Events

Epilepsy Boot Camp
April 20-21, 2012
Charleston SC
Presented by the Medical University of South Carolina, MUSC Comprehensive Epilepsy Program, MUHA Neuroscience Service Line, MUSC Department of Neurosciences and the Office of Continuing Medical Education
Epilepsy Boot Camp is a two-day intense, comprehensive epilepsy course for health care providers. The topics on day one will begin with essential facts about seizures, and will progress through seizure types, the impact of epilepsy, and special needs of particular patient groups. The first day will continue with a thorough introduction to state of the art diagnostic options. The second day will be a full review of current treatment options, pharmacologic treatment, neurostimulation and special diets for epilepsy. In the afternoon, more advanced topics such as epilepsy surgeries and functional brain-mapping will be reviewed. Breakout sessions will include Seizure first aid (the first responder), epilepsy genetics, nonepileptic events (pseudoseizures) and early intervention for refractory epilepsy.

Course Objectives
At the conclusion of this meeting, participants should be able to:
• Describe seizure disorders and discuss the broad impact of epilepsy.
• Outline both widely-available and specialized state-of-the-art diagnostic options for patients with epilepsy.
• Discuss the wide range of medical, dietary, neuromodulatory, and surgical treatments for seizures and epilepsy and implement therapeutic strategies that are most effective for specific epilepsy types.

For more information, contact Elizabeth Gossen at 843-876-1925 or gossen@musc.edu

Neurosciences Research Day
May 3rd, 2012
MUSC Colbert Education Center and Library

The Department of Neurosciences organizes an annual “Neurosciences Research Day”. It is an initiative to promote academic research among the residents and the faculty. The residents and fellows of Neurology and Neurosurgery participate by presenting research projects. Faculty experts from the divisions of neurosurgery, neurology and basic neurosciences judge these presentations and award the participants.

April 20th – Abstract Deadline

This year interns and fellows are not required to participate, but are certainly welcome to do so. Please contact Dr. Angela Hays if you plan to present so that a spot can be reserved. Please turn in your abstracts to Olivia Burch, Emily Nelson, or Dr. Hays by April 20th for inclusion in the brochure. If you need a copy of the abstract submission form please contact Dr. Hays.

http://academicdepartments.musc.edu/neurosciences/education/neurosurgery_residency/news_publications/neurosciences_day.html

Scholarship Recipient
Congratulations to Nolan Williams, M.D.

Congratulations, on behalf of the Graduate Education Subcommittee (GES), and Cynthia L. Comella, MD, FAAN, Chair of the Education Committee, we are pleased to let you know that you have been selected as one of the American Academy of Neurology’s (AAN) 2012 Annual Meeting Resident Scholarship recipients. The scholarship of $1,000 ($500 if located within 50 miles of New Orleans) will be paid after the Annual Meeting, to your institution in the form of an educational grant for reimbursement of your Annual Meeting expenses associated with attendance at the AAN Annual Meeting to be held in New Orleans, LA April 21 through April 28, 2012.

Nolan Williams, MD: Congratulations, On behalf of the Graduate Education Subcommittee (GES), and Cynthia L. Comella, MD, FAAN, Chair of the Education Committee, we are pleased to let you know that you have been selected as one of the American Academy of Neurology’s (AAN) 2012 Annual Meeting Resident Scholarship recipients.

Quick Updates
Posters
Dr. Tsai had a poster accepted for AAP in February

CNBC Article
Jane Joseph, Ph.D., Director of the Neuroimaging Division of the Medical University of South Carolina, is a part of a research team whose work was discussed in a CNBC article entitled Risk Is In The Brain of the Beholder, by Jeffrey Weiss.

To read the article visit the below link:
http://www.cnbc.com/id/44501913/Risk_Is_In_The_Brain_of_The_Beholder

Neurosciences Service Line
MUSC Stroke Center News
November 2011 – January 2012

Announcements
Welcome!
• Lidia Yamada, Research Specialist
• Lynette Brown, Program Coordinator
• Bobbie Lynn Stasa, Administrative Specialist
• Megan McDonough, Administrative Assistant

Publications
https://www.aamc.org/icollaborative/r4r/264102/resource165.html

Awards
• November 1, 2011 – Health Care Heroes Finalists
• Named for 2011 - Charleston Regional Business Journal, Physician Finalist Dr. Edward Jauch

Community Engagement:
November 2, 2011 - Fort Dorchester Biotechnology Class. Robert J. Adams, MD and staff – Judy Luden, CCRP and Lidia Yamada, MD - all did a great job with presentations, demos, and answering questions from students for their project on stroke

Stroke Conference Highlights
MUSC stroke center had a large group attending the stroke conference in February. Below are a few highlights from the meeting:

1) The Comprehensive Stroke Center at MUSC received the American Heart Association/American Stroke Association’s Get With The Guidelines Stroke Gold Plus Quality Achievement Award for 2011.

2) SAMMPRIS (a clinical trial at MUSC) had its’ own symposium at the conference, which attracted a lot of attention.

3) 7 investigators from different departments at MUSC made 8 presentations on the conference.

4) Dr. Edward Jauch is the current President of the stroke council for the American Heart Association.

Part of the MUSC Stroke Team at the February conference.
### SAMMPRIS Related Lectures

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Session</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Derdeyn</td>
<td>Intracranial Stenting and SAMMPRIS Trial</td>
<td>Lessons Learned for Current Management and Future Trials</td>
</tr>
<tr>
<td>David Liebeskind</td>
<td>Cerebrovascular Occlusive Disease</td>
<td>Collaterals Determine Risk of Early Territorial Stroke and Hemorrhage in the SAMMPRIS Trial</td>
</tr>
<tr>
<td>Colin Derdeyn</td>
<td>Plenary session</td>
<td>Detailed Analysis of the 30-day Outcomes in the Stenting Arm of the SAMMPRIS Trial</td>
</tr>
<tr>
<td>Tanya Turan</td>
<td>Community/Risk Factors</td>
<td>Impact of an Aggressive Medical Management Protocol on Early Risk Factor Measures in the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) Trial</td>
</tr>
<tr>
<td>Helmi Lutsep</td>
<td>Late-Breaking Science</td>
<td>Outcome of Patients in the SAMMPRIS Trial Who Had Failed Antithrombotic Therapy at Study Enrollment</td>
</tr>
</tbody>
</table>

### Presentations by MUSC Researchers

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Session</th>
<th>Topic</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wayne Feng</td>
<td>Junior Investigator Symposium</td>
<td>Predicting Motor Outcome at 3 Months Post-stroke</td>
<td>February 01, 2012</td>
</tr>
<tr>
<td>Catherine Dillon</td>
<td>Outcomes, Quality and Health Services</td>
<td>Using Standardized Web-based Tests in Clinical Trials to Improve Investigator and Coordinator Protocol Familiarity: Experience from Antihypertensive Treatment of Acute Cerebral Hemorrhage II trial</td>
<td>February 2, 2012</td>
</tr>
<tr>
<td>Saeid Taheri</td>
<td>Acute Neuroimaging</td>
<td>Contrast Enhanced MRI with a Reduced Dose of Gadolinium for Measurement of Blood to Brain Influx Rate in Cerebrovascular Diseases</td>
<td>February 2, 2012</td>
</tr>
<tr>
<td>Abby S Kazley</td>
<td>Outcomes, Quality and Health Services</td>
<td>Increased rt-PA Utilization Will Decrease Healthcare Costs in SC</td>
<td>February 01, 2012</td>
</tr>
<tr>
<td>Edward Jauch</td>
<td>Plenary session</td>
<td>Stroke Council Update</td>
<td>February 02, 2012</td>
</tr>
</tbody>
</table>
9 East Updates

Awards
9 East received the silver award for hand washing compliance.

Congratulations to Emily Andrews from 9 East for being chosen as one of the five recipients of the MUSC Clinical Scholar’s Program. Emily’s research focus will be on SILENT hours, currently being piloted in 9 East.

SILENT hours is a project that is being piloted on 9 East. Research shows that patient outcomes and satisfaction scores improve when the hospital environment is quiet. 9 East is a busy unit, yet daily quiet hours are being implemented from 1400-1600 and 0030-0330 to ensure that our patients have some time to rest and relax from the busy activity of the unit. The bedside staff and other ancillary staff has been educated about the importance of our SILENT hours. The project began on January 23 and continues to be amended in order to provide the best outcomes for the patients on 9 East.

MUSC Website’s New Look
Dr. Greenberg sent out a letter in mid-December outlining his plans to have all of our MUSC messaging reflect the branding effort: Changing What’s Possible. Since some of the most visible messages we have are our websites, we have undertaken a campaign to realign all MUSC websites with the brand campaign. That means that MUSC health.com and MUSC.edu will be refreshed with a new, unified look and feel as well as improved navigation.

To view the new look visit: MUSC health.com

Promotional
An MUSC ambulance will be “wrapped” in the near future with one side dedicated to promoting the Comprehensive Stroke Center and the other the Chest Pain Center.

Community Events
February 22nd Drs. Chaudry and Turner did a wonderful job providing the AHA/ASA Circle of Red donor group with a behind the scenes tour of the NIR Suite. The event was hosted by AHA/ASA for their “high-end” female donors. The group included a board member of SC ETV, a Boeing executive and the owner of the Moultrie News. AHA/ASA thought it went great and has already said they would like to do a similar event in the Spring around Stroke Awareness month in April.

MUSC Community Blog
Dr. Mintzer was recently featured on Channel 2 News and MUSC Community Blog. To view the article Dr. Mintzer Addresses the question of Alzheimer’s Disease Treatment with Targretin visit: http://newsroom.muschealth.com/index.php/2012/02/dr-mintzer-addresses-the-question-of-alzheimers-disease-treatment-with-targretin/

Israeli News Feature
MUSC mentioned in article South Carolina woos Israeli innovation. To read the article visit:
http://www.israel21c.org/social-action/south-carolina-woos-israeli-innovation

Scholarship recipient Emily Andrews.

MUSC Community Blog
Dr. Mintzer was recently featured on Channel 2 News and MUSC Community Blog. To view the article Dr. Mintzer Addresses the question of Alzheimer’s Disease Treatment with Targretin visit: http://newsroom.muschealth.com/index.php/2012/02/dr-mintzer-addresses-the-question-of-alzheimers-disease-treatment-with-targretin/

9 East Team Photo.
Publications

Peter Kalivas, Ph.D., co-authored the article ‘Heroin relapse requires long-term potentiation-like plasticity mediated by NMDA2b-containing receptors’ which was recently published in PNAS.


Shen, Z., Lu Z, Chhatbar PY, O’Herron and Kara P (2012). An artery-specific fluorescent dye for studying neurovascular coupling in vivo. Nature Methods 9, 273-276. With the Online Methods and Suppl. Figs & Notes; this is a 52 page paper. The seemingly simple story covers 5 species. But only three species are mentioned in the short abstract. The work spanned the gamut of techniques and will have translational impact.

To view this article visit:

Employee Update

Goodbye and Good Luck

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pava, Matthew</td>
<td>Graduate Assistant</td>
</tr>
<tr>
<td>Tompa, Tamas</td>
<td>PD</td>
</tr>
<tr>
<td>Huits, Martijn</td>
<td>Student</td>
</tr>
<tr>
<td>Crosby, Maggie</td>
<td>Student</td>
</tr>
<tr>
<td>Padula, Audrey</td>
<td>Research Spec</td>
</tr>
<tr>
<td>Xu, Minfu</td>
<td>PD</td>
</tr>
<tr>
<td>Reissner, Kate</td>
<td>RG</td>
</tr>
<tr>
<td>Currie, Kaylin</td>
<td>vol</td>
</tr>
<tr>
<td>Hilton, William</td>
<td>Visiting Scholar</td>
</tr>
</tbody>
</table>

Welcome New Employees

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gibson, Cameron</td>
<td>Volunteer</td>
</tr>
<tr>
<td>McGonigal, Justin</td>
<td>Volunteer</td>
</tr>
<tr>
<td>Wilson, Jack</td>
<td>Postdoc</td>
</tr>
<tr>
<td>Tompa, Tamas</td>
<td>Volunteer</td>
</tr>
<tr>
<td>Hilton, William</td>
<td>Added Source</td>
</tr>
<tr>
<td>Madisetti, Mohan</td>
<td>Faculty</td>
</tr>
<tr>
<td>Naselaris, Thomas</td>
<td>RG</td>
</tr>
<tr>
<td>Padula, Audrey</td>
<td>RG</td>
</tr>
<tr>
<td>Hughes, Hannah</td>
<td>student</td>
</tr>
<tr>
<td>Hamid, Ramiz</td>
<td>Postdoc</td>
</tr>
<tr>
<td>Reissner, Kate</td>
<td>student</td>
</tr>
<tr>
<td>Currie, Kaylin</td>
<td>PD</td>
</tr>
<tr>
<td>Canterbury, Melanie</td>
<td>RG</td>
</tr>
<tr>
<td>Hergatt, Jennifer</td>
<td>RG</td>
</tr>
<tr>
<td>Mahaffey, Brenton</td>
<td>vol</td>
</tr>
<tr>
<td>Sprouse, Mc Kenna</td>
<td>vol</td>
</tr>
<tr>
<td>Benton, Erik</td>
<td>RG</td>
</tr>
<tr>
<td>Brown, Lynette</td>
<td>RG</td>
</tr>
<tr>
<td>Piepho, Shelby</td>
<td>faculty</td>
</tr>
<tr>
<td>Schaidle, Sarah</td>
<td>Research Specialist</td>
</tr>
<tr>
<td>Burnham, Nathan</td>
<td>Program Coordinator</td>
</tr>
<tr>
<td>McLintock, Susan</td>
<td>Administrative Specialist</td>
</tr>
<tr>
<td>Voeks, Jennifer</td>
<td>Administrative Assistant</td>
</tr>
</tbody>
</table>
# Clinical Trials

The Following Studies are Actively Enrolling Subjects

## Alzheimer’s

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Sponsor</th>
<th>Principal Investigator</th>
<th>Study Coordinator</th>
<th>Contact Phone/Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEREGENE</td>
<td>A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects with Mild to Moderate Alzheimer’s Disease</td>
<td>National Institute on Aging and Ceregene, Inc.</td>
<td>Jacobo Mintzer M.D., M.B.A. and David Bachman M.D.</td>
<td>Beth Safrit, NP</td>
<td>843-740-1592</td>
</tr>
<tr>
<td>BAPI</td>
<td>A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy and Safety Trial of Bapineuzumab in Subjects with Mild to Moderate Alzheimer’s Disease</td>
<td>Pfizer Pharmaceuticals</td>
<td>Jacobo Mintzer M.D., M.B.A. and David Bachman M.D.</td>
<td>Jan Watts, RN</td>
<td>843-740-1592</td>
</tr>
<tr>
<td>CITAD</td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Study of Citalopram for the treatment of Agitation in Alzheimer’s Disease</td>
<td>National Institute of Health</td>
<td>Jacobo Mintzer M.D., M.B.A. and David Bachman M.D.</td>
<td>Amanda Watts</td>
<td>843-740-1592</td>
</tr>
<tr>
<td>ABBY</td>
<td>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to evaluate the efficacy and safety of Crenezumab in patients with mild to moderate Alzheimer’s Disease (ABBY)</td>
<td>Genentech, Inc.</td>
<td>Jacobo Mintzer M.D., M.B.A. and David Bachman M.D.</td>
<td>Arthur Williams</td>
<td>843-740-1592</td>
</tr>
</tbody>
</table>

## Spine Trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Sponsor</th>
<th>Principal Investigator</th>
<th>Study Coordinator</th>
<th>Contact Phone/Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>KAST</td>
<td>The KIVA™ System as a Vertebral augmentation Treatment- A Safety &amp; Effectiveness Trial</td>
<td>Benvenue Medical</td>
<td>Bruce Frankel, M.D.</td>
<td>Michele DeCandio, RN</td>
<td>843-792-9016 <a href="mailto:decandio@musc.edu">decandio@musc.edu</a></td>
</tr>
<tr>
<td>NanOSS</td>
<td>A Prospective, Multi-Center, Nonrandomized study to assess Lumbar Fusion Using Interbody Cages with Autograft in Conjunction with Instrumented Posterolateral Gutter Fusions Using NANOSS BA™</td>
<td>Pioneer Surgical Technology</td>
<td>Abbay Varma, M.D.</td>
<td>Michele DeCandio, RN</td>
<td>843-792-9016 <a href="mailto:decandio@musc.edu">decandio@musc.edu</a></td>
</tr>
<tr>
<td>Study Trials</td>
<td>Title</td>
<td>Sponsor</td>
<td>Principal Investigator</td>
<td>Study Coordinator</td>
<td>Contact Phone/Email</td>
</tr>
<tr>
<td>-------------</td>
<td>-------</td>
<td>---------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>BRIVARACETAM</td>
<td>This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200 mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.</td>
<td>UCB, Inc.</td>
<td>Jonathan Halford, M.D.</td>
<td>Ashley Gantt</td>
<td>843-792-7118 <a href="mailto:gantt@musc.edu">gantt@musc.edu</a></td>
</tr>
<tr>
<td>CARBAMAZEPINE - IV</td>
<td>The purpose of the study is to assess the safety and tolerability of intravenous (IV) carbamazepine (CBZ) administered as multiple 15 minute infusions to adult patients with epilepsy on stable higher doses of oral CBZ.</td>
<td>Lundbeck, Inc.</td>
<td>Jonathan Halford, M.D.</td>
<td>Ashley Gantt</td>
<td>843-792-7118 <a href="mailto:gantt@musc.edu">gantt@musc.edu</a></td>
</tr>
<tr>
<td>Sabril®</td>
<td>A prospective, open-label study of the structure and function of the retina in adult patients with refractory complex partial seizures treated with vigabatrin (Sabril®)</td>
<td>Lundbeck, Inc.</td>
<td>Ekrem Kutluay, M.D.</td>
<td>Ashley Gantt</td>
<td>843-792-7118 <a href="mailto:gantt@musc.edu">gantt@musc.edu</a></td>
</tr>
<tr>
<td>Movement Disorders</td>
<td>Title</td>
<td>Sponsor</td>
<td>Principal Investigator</td>
<td>Study Coordinator</td>
<td>Contact Phone/Email</td>
</tr>
<tr>
<td>CD-PROBE</td>
<td>CD PROBE - Cervical Dystonia - Patient Registry for Observation of Botox® Efficacy</td>
<td>Allergan Sales, LLC</td>
<td>Vanessa Hinson, M.D., Ph.D.</td>
<td>Jennifer Zimmerman, RN</td>
<td>843-792-9115 <a href="mailto:zimmerj@musc.edu">zimmerj@musc.edu</a></td>
</tr>
<tr>
<td>FS Zone</td>
<td>Parkinson's Disease Neuroprotection Clinical Trial Center - FS Zone Supplemental Study</td>
<td>NIH/NINDS</td>
<td>Vanessa Hinson, M.D., Ph.D.</td>
<td>Jennifer Zimmerman, RN</td>
<td>843-792-9115 <a href="mailto:zimmerj@musc.edu">zimmerj@musc.edu</a></td>
</tr>
<tr>
<td>Phytopharm</td>
<td>A Phase II, multi-centre, randomized, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane™ (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson's disease when administered once daily for 28 weeks.</td>
<td>Phytopharm Plc (ICON Clinical Resarch)</td>
<td>Gonzalo Revuelta, D.O.</td>
<td>Jennifer Zimmerman, RN</td>
<td>843-792-9115 <a href="mailto:zimmerj@musc.edu">zimmerj@musc.edu</a></td>
</tr>
<tr>
<td>Synosia</td>
<td>A double-blind, randomized, placebo-controlled study of the safety and efficacy of SYN115 as adjunctive therapy in levodopa-treated Parkinson's subjects with end of dose wearing off</td>
<td>Synosia Therapeutics, Inc.</td>
<td>Gonzalo Revuelta, D.O.</td>
<td>Jennifer Zimmerman, RN</td>
<td>843-792-9115 <a href="mailto:zimmerj@musc.edu">zimmerj@musc.edu</a></td>
</tr>
<tr>
<td>Crest-E</td>
<td>Creatine Safety, Tolerability, and Efficacy in Huntington’s Disease: CREST-E</td>
<td>Massachusetts General Hospital</td>
<td>Gonzalo Revuelta, D.O.</td>
<td>Amy DeLambo, ACNP</td>
<td>843-792-7262 <a href="mailto:delambo@musc.edu">delambo@musc.edu</a></td>
</tr>
</tbody>
</table>
### Brain & Spine Tumor Program Clinical Trials

<table>
<thead>
<tr>
<th>Study/CTO #</th>
<th>Title</th>
<th>Principal Investigator</th>
<th>Study Coordinator</th>
<th>Coordination Site/ Trial Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glioblastoma, Adjuvant 101481</td>
<td>RTOG 0837: Randomized, Phase II, Double-Blind, Placebo-Controlled trial of conventional chemoradiation and adjuvant temozolomide plus cediranib versus conventional chemoradiation and adjuvant temozolomide plus placebo in patients with newly diagnosed glioblastoma.</td>
<td>Pierre Giglio, MD Tel: 843-792-6592 <a href="mailto:giglio@musc.edu">giglio@musc.edu</a></td>
<td>John Keller Tel: 843-792-1286 <a href="mailto:kellej@musc.edu">kellej@musc.edu</a></td>
<td>Clinical Trials Office (Hollings Cancer Center) RTOG 0837</td>
</tr>
<tr>
<td>DCVax®</td>
<td>A Phase II Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme</td>
<td>Pierre Giglio, MD Tel: 843-792-6592 <a href="mailto:giglio@musc.edu">giglio@musc.edu</a></td>
<td>Michele DeCandio, RN Tel: 843-792-9016 E-mail: <a href="mailto:decandio@musc.edu">decandio@musc.edu</a></td>
<td>Translational Research Unit (Neurosciences)/Northwest Biotherapeutics, Inc.</td>
</tr>
<tr>
<td>Crizotinib</td>
<td>The Efficacy of PF-02341066 (Crizotinib), a Dual ALK/c-Met Inhibitor in Inhibiting Growth of Glioblastoma</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592 arabinda Das, Ph.D. E-mail: <a href="mailto:dasa@musc.edu">dasa@musc.edu</a></td>
<td>Michele DeCandio, RN Tel: 843-792-9016 E-mail: <a href="mailto:decandio@musc.edu">decandio@musc.edu</a></td>
<td>Translational Research Unit (TRU)/Pfizer</td>
</tr>
<tr>
<td>The Effect of Garlic Compounds on Fresh Human Glioma Biopsies</td>
<td>The Effect of Garlic Compounds on Fresh Human Glioma Biopsies</td>
<td>Pierre Giglio, MD Tel: 843-792-6592</td>
<td>Michele DeCandio, RN Tel: 843-792-9016 E-mail: <a href="mailto:decandio@musc.edu">decandio@musc.edu</a></td>
<td>Translational Research Unit (Neurosciences)</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment with Bevacizumab for Progressive Disease</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592 Joseph Helpern, Ph.D. E-mail: <a href="mailto:helpern@musc.edu">helpern@musc.edu</a></td>
<td>John Keller Tel: 843-792-1286 E-mail: <a href="mailto:kellej@musc.edu">kellej@musc.edu</a></td>
<td>Clinical Trials Office (Hollings Cancer Center)/HCC Translational Research Grant</td>
</tr>
<tr>
<td>Anaplastic Glioma, Adjuvant (1) 101450</td>
<td>RTOG EORTC 0834/26053 22054, “Phase III Trial on concurrent and adjuvant temozolomide chemotherapy in Non-1p/19q deleted anaplastic glioma.”</td>
<td>Pierre Giglio, MD Tel: 843-792-6592 <a href="mailto:giglio@musc.edu">giglio@musc.edu</a></td>
<td>John Keller Tel: 843-792-1286 <a href="mailto:kellej@musc.edu">kellej@musc.edu</a></td>
<td>Clinical Trials Office (Hollings Cancer Center) The CATNON Intergroup Trial (RTOG 834)</td>
</tr>
<tr>
<td>Anaplastic Glioma, Adjuvant (2) 101449</td>
<td>Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concurrent and Adjuvant Temozolomide for Patients with lp/19q Codeleted Anaplastic Glioma.</td>
<td>Pierre Giglio, MD Tel: 843-792-6592 <a href="mailto:giglio@musc.edu">giglio@musc.edu</a></td>
<td>John Keller Tel: 843-792-1286 <a href="mailto:kellej@musc.edu">kellej@musc.edu</a></td>
<td>Clinical Trials Office (Hollings Cancer Center) NCCTG</td>
</tr>
<tr>
<td>Low Grade Glioma, Progressive</td>
<td>Low Grade Glioma, Progressive: CTO: 101399 ECOG E3F05, “Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas.”</td>
<td>Pierre Giglio, MD Tel: 843-792-6592 <a href="mailto:giglio@musc.edu">giglio@musc.edu</a></td>
<td>John Keller Tel: 843-792-1286 <a href="mailto:kellej@musc.edu">kellej@musc.edu</a></td>
<td>Clinical Trials Office (Hollings Cancer Center) ECOG (Study E3F05); RTOG Endorsed</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Title, Agency</td>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adams, R</td>
<td>Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease In Children</td>
<td>$45,865</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chimowitz, M</td>
<td>SmartState Stroke Countess Paolozzi Endowed Chair</td>
<td>$59,904</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feng, W</td>
<td>S-STREAM: A Multi-Center, Observational Study to Evaluate the Simplified-Stroke REhabilitation Assessment of Movement</td>
<td>$163,925</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giglio, P</td>
<td>The Efficacy of PF-02341066 (Crizotinib), a Dual ALK/c-Met Inhibitor in Inhibiting Growth of Glioblastoma</td>
<td>$125,784</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giglio, P</td>
<td>A Phase II, Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme</td>
<td>$172,855</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Halford, J</td>
<td>Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients with Epilepsy</td>
<td>$134,346</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Halford, J</td>
<td>Brivaracetam Efficacy and Safety Study in Subject with Partial Onset Seizures</td>
<td>$11,700</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Halford, J</td>
<td>An Open-Label, Multi-Center, Follow-Up Study to Evaluate the Long-Term, Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older with Partial Onset Seizures</td>
<td>$14,300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hinson, V</td>
<td>CD Probe - Cervical Dystonia - Patient Registry for Observation of BOTOX Efficacy</td>
<td>$81,565</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hinson, V</td>
<td>Parkinson’s Disease Neuroprotection Clinical Trial Center</td>
<td>$54,692</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kinsman, S</td>
<td>Emergency Use Protocol for EPI-743 in Acutely Ill Patients with Inherited Mitochondrial Respiratory Chain Disease within 90 Days of End of Life Care</td>
<td>$307,219</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lackland, D</td>
<td>Etiology of Geographic and Racial Differences in Stroke</td>
<td>$80,386</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mahler, S</td>
<td>VTA Glutamate and Orexin Involvement in Cue Reinstatement of Drug Seeking</td>
<td>$52,190</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Project Description</td>
<td>Amount</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mintzer, J</td>
<td>Citalopram Treatment for Agitation in Alzheimer Dementia Johns Hopkins Univ.</td>
<td>$130,068</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mintzer, J</td>
<td>A Phase 3, Multi-Center, Long-Term, Safety and Tolerability Trial of Bapineuzumab in Subjects with Alzheimer’s Disease Who are Apolipoprotein E4 Carriers and Participated in Study 3133K1-3001 Icon Clinical Research, Inc.</td>
<td>$19,305</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mulholland, P</td>
<td>Stress and Ethanol Dependence: SK Channels and Glutamate NIH/NIAAA</td>
<td>$183,680</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parsegian, A</td>
<td>Impact of Meth Self-Administration on GLU and DA in the Corticoaccumbens Pathway NIH/NIDA</td>
<td>$41,242</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reissner, K</td>
<td>Contributions of Glial Glutamate Transport and Transmission to Drug Abuse NIH/NIDA</td>
<td>$120,228</td>
<td></td>
<td></td>
</tr>
<tr>
<td>See, R</td>
<td>Striatal Mechanisms of Relapse to Cocaine Seeking NIH/NIDA</td>
<td>$254,916</td>
<td></td>
<td></td>
</tr>
<tr>
<td>See, R</td>
<td>Striatal Mechanisms of Relapse to Cocaine Seeking NIH/NIDA</td>
<td>$28,324</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turner, R</td>
<td>Codman Training Grant - Work Order #2 Codman and Shurtleff, Inc.</td>
<td>$17,974</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waters, R</td>
<td>PACD Scholar: Dr. R. Parrish Waters Univ. of South Carolina</td>
<td>$4,777</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Woodward, J</td>
<td>Neural Actions of Toluene NIH/NIDA</td>
<td>$313,726</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Thank you for your contributions. For questions, comments or to make a submission please contact:

Emma C. Vought at vought@musc.edu

Medical University of South Carolina Neurosciences